An *editorial* brief, not a prescriber

Who we are

Script Retatrutide is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'script' in the domain name is editorial framing — a position the publisher occupies relative to the prescribing landscape, not a claim about the site's services. We chose the name because that is the search term readers actually type, and the most useful thing this site can do is give those readers an honest, sourced answer about what the prescribing landscape actually looks like for an investigational compound in Phase 3 trials.

What we cover

The brief is organized around the published research on retatrutide: mechanism of triple agonism (GIPR / GLP-1R / GCGR), Phase 1 pharmacokinetics, Phase 2 obesity and type 2 diabetes readouts, the Phase 2a MASLD substudy, the ongoing TRIUMPH Phase 3 program, and the U.S. regulatory framework for prescribing and compounding investigational compounds. Every quantitative claim is tied to a primary source.

We deliberately do not cover topics outside the published literature. We do not publish vendor reviews. We do not maintain a 'where to buy' guide. We do not summarize anecdotal user reports.

Editorial standards

Three rules govern what gets published here. First, every quantitative claim is sourced to peer-reviewed literature, a regulatory document, or a ClinicalTrials.gov entry. Second, doses, schedules, and titration ladders are described as they appear in published trials — not as recommendations for use. Third, regulatory framing is drawn from primary FDA documents and the statutory text of FDCA 503A and 503B, not from second-hand summaries.

When the literature is genuinely uncertain — for example, long-term cardiovascular outcomes, which TRIUMPH-3 is still characterizing — we say so. We do not extrapolate Phase 2 readouts into Phase 3 predictions, and we do not predict approval timelines tighter than the program's own design will support.

What we are not

We are not affiliated with the sponsor of the retatrutide development program. We have no commercial relationship with any compounding pharmacy, telehealth platform, peptide vendor, or pharmaceutical company. We do not facilitate access to retatrutide and have no means of doing so. If you arrived here looking for a prescription, the brief explains, with citations, why no clinician can lawfully write one outside a clinical trial.

We are also not a substitute for individualized medical advice. Readers with specific clinical questions should consult a qualified healthcare provider.

Corrections

If you spot a factual error, a citation mismatch, or a statement that has been overtaken by newer published evidence, please reach out via /contact. We update the brief when the literature warrants it.